EXEL: Hold with a $50.55 price target

Year-to-date profit has improved, but working capital is growing faster than sales.

Target for 2027-09-15: $50.55 USD, -9.9% versus the $56.12 weekly close on 2026-09-11. Price return only; dividends, fees and tax excluded.

Over 1 year (2025-09-12 to 2026-09-11), price changed +43.3% and trailing EPS changed +42.7%. A wider gap changes the earnings multiple; it does not establish fair value.

Across 2 completed quarters since 2026-01-02, net income was 422.5m versus 344.5m in the matching prior-year periods (USD). Check whether the latest quarter changes that direction.

Over one year, the stock changed +43.3% against +19.7% for Healthcare (XLV). The gap is +23.6 percentage points. These are price returns, before dividends.

Inventory changed +22.3%, against sales of +10.6%, from the same quarter last year. This can tie up cash. Acquisitions, payment timing and seasonality also need checking.

Cash after capital spending / profit: 1.4× for EXEL, against 1.8× across 6 comparable peers.

Compare the next results with the trailing margin of 39.9% and the annual-history median of 20.0%. A historical median is context, not a forecast.

The latest quarterly margin changed +1.9 percentage points from a year earlier. Check sales volumes, pricing and unusual gains in the next filing.

Recheck the valuation gap alongside profitability and growth after new results. A discount alone does not establish value.

Starting annual sales growth: 10.3%.

Net profit margin: 25.72%.

Review recorded on 2026-09-16. This is a dated summary of an automated company valuation. The full report includes the financial evidence, alternative scenarios and review history. Consult the latest report before using an earlier target. Automated model research, not personal investment advice. Targets depend on assumptions; returns are not guaranteed.